Fevipiprant is a potent and selective DP2 antagonist, which as such is well-tolerated and has shown anti-inflammatory effects such as reduced eosinophilic airway inflammation and declined airway smooth muscle mass in phase 2 clinical trials with patients suffering from severe, uncontrolled asthma [34–36]. Here, PTGDR2 is linked to asthma.